PF-Atlas › Treatments › PLN-74809

PLN-74809

Dual integrin inhibitor — blocks TGF-β activation at source via αvβ6/αvβ1

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase II/III
Evidence level
Level 2 (Phase II/III)
Mechanism class
Dual integrin inhibitor — blocks TGF-β activation at source via αvβ6/αvβ1
Timeline
2-4 years
Risk profile
Low-Medium
Developer
Pliant Therapeutics / UCSF
Key researchers
D. Sheppard

Overview

INTEGRIS-IPF trial. Dose-dependent FVC preservation. More targeted than current SOC.

How PLN-74809 fits into IPF treatment

PLN-74809 is classified as Level 2 (Phase II/III) at the Phase II/III stage. Explore how it compares to other options and where it sits in the development pipeline:

PLN-74809 drug profileDual integrin inhibitor — blocks TGF-β activation at source via αvβ6/αvβ1Clinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about PLN-74809 for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.